Mirum Pharmaceuticals IncNASDAQ:MIRM
- LAST PRICE24.6500
- TODAY'S CHANGE (%)-0.3400 (-1.3605%)
- Bid / Lots24.6500/ 2
- Ask / Lots24.7000/ 2
- Open / Previous Close24.7400 / 24.9900
- Day Range
- 52 Week Range
- Volume149,597
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MIRM |
|---|---|---|
| 09:32 ET | 6530 | 24.74 |
| 09:36 ET | 300 | 24.64 |
| 09:41 ET | 700 | 24.63 |
| 09:43 ET | 1341 | 24.635 |
| 09:45 ET | 600 | 24.65 |
| 09:48 ET | 1000 | 24.63 |
| 09:50 ET | 100 | 24.63 |
| 09:52 ET | 400 | 24.59 |
| 09:54 ET | 1200 | 24.56 |
| 09:56 ET | 500 | 24.51 |
| 09:57 ET | 400 | 24.52 |
| 09:59 ET | 1653 | 24.5 |
| 10:01 ET | 1200 | 24.56 |
| 10:03 ET | 1200 | 24.64 |
| 10:06 ET | 585 | 24.58 |
| 10:10 ET | 3100 | 24.57 |
| 10:12 ET | 200 | 24.58 |
| 10:14 ET | 500 | 24.59 |
| 10:17 ET | 2349 | 24.6 |
| 10:19 ET | 3312 | 24.53 |
| 10:21 ET | 200 | 24.52 |
| 10:24 ET | 300 | 24.5 |
| 10:26 ET | 300 | 24.565 |
| 10:30 ET | 2601 | 24.83 |
| 10:35 ET | 100 | 24.76 |
| 10:39 ET | 100 | 24.85 |
| 10:42 ET | 770 | 24.81 |
| 10:46 ET | 500 | 24.805 |
| 10:48 ET | 100 | 24.805 |
| 10:50 ET | 400 | 24.77 |
| 10:51 ET | 900 | 24.75 |
| 10:53 ET | 1113 | 24.65 |
| 10:57 ET | 300 | 24.61 |
| 11:00 ET | 3423 | 24.61 |
| 11:02 ET | 1200 | 24.62 |
| 11:04 ET | 200 | 24.6 |
| 11:06 ET | 700 | 24.61 |
| 11:09 ET | 200 | 24.64 |
| 11:11 ET | 1600 | 24.65 |
| 11:13 ET | 500 | 24.66 |
| 11:15 ET | 100 | 24.62 |
| 11:20 ET | 3516 | 24.61 |
| 11:22 ET | 2800 | 24.5 |
| 11:26 ET | 2463 | 24.49 |
| 11:27 ET | 300 | 24.51 |
| 11:29 ET | 200 | 24.44 |
| 11:31 ET | 600 | 24.46 |
| 11:33 ET | 2800 | 24.49 |
| 11:36 ET | 300 | 24.51 |
| 11:38 ET | 1400 | 24.5775 |
| 11:44 ET | 200 | 24.53 |
| 11:45 ET | 3265 | 24.66 |
| 11:47 ET | 300 | 24.611 |
| 11:49 ET | 100 | 24.61 |
| 11:51 ET | 118 | 24.6664 |
| 11:56 ET | 200 | 24.65 |
| 12:00 ET | 1200 | 24.71 |
| 12:02 ET | 1300 | 24.68 |
| 12:05 ET | 279 | 24.5801 |
| 12:07 ET | 300 | 24.67 |
| 12:09 ET | 1000 | 24.6266 |
| 12:12 ET | 100 | 24.61 |
| 12:18 ET | 700 | 24.65 |
| 12:23 ET | 500 | 24.68 |
| 12:25 ET | 911 | 24.68 |
| 12:27 ET | 100 | 24.66 |
| 12:30 ET | 100 | 24.66 |
| 12:38 ET | 200 | 24.65 |
| 12:39 ET | 600 | 24.655 |
| 12:41 ET | 412 | 24.65 |
| 12:43 ET | 100 | 24.65 |
| 12:45 ET | 2618 | 24.605 |
| 12:54 ET | 580 | 24.6363 |
| 12:56 ET | 522 | 24.67 |
| 12:57 ET | 100 | 24.65 |
| 12:59 ET | 100 | 24.65 |
| 01:03 ET | 301 | 24.64 |
| 01:06 ET | 200 | 24.65 |
| 01:10 ET | 100 | 24.66 |
| 01:12 ET | 400 | 24.65 |
| 01:14 ET | 300 | 24.62 |
| 01:15 ET | 100 | 24.665 |
| 01:21 ET | 400 | 24.59 |
| 01:28 ET | 300 | 24.59 |
| 01:30 ET | 200 | 24.655 |
| 01:35 ET | 200 | 24.65 |
| 01:37 ET | 300 | 24.65 |
| 01:39 ET | 100 | 24.655 |
| 01:44 ET | 100 | 24.655 |
| 01:46 ET | 890 | 24.65 |
| 01:51 ET | 300 | 24.64 |
| 01:53 ET | 200 | 24.63 |
| 02:00 ET | 200 | 24.66 |
| 02:02 ET | 700 | 24.65 |
| 02:08 ET | 300 | 24.66 |
| 02:11 ET | 200 | 24.655 |
| 02:15 ET | 300 | 24.64 |
| 02:18 ET | 100 | 24.61 |
| 02:20 ET | 100 | 24.63 |
| 02:22 ET | 100 | 24.62 |
| 02:27 ET | 500 | 24.61 |
| 02:33 ET | 100 | 24.575 |
| 02:36 ET | 100 | 24.57 |
| 02:38 ET | 100 | 24.59 |
| 02:40 ET | 200 | 24.58 |
| 02:44 ET | 200 | 24.57 |
| 02:45 ET | 600 | 24.58 |
| 02:47 ET | 100 | 24.57 |
| 02:49 ET | 500 | 24.64 |
| 02:54 ET | 100 | 24.66 |
| 02:56 ET | 800 | 24.65 |
| 03:02 ET | 300 | 24.64 |
| 03:03 ET | 298 | 24.6202 |
| 03:05 ET | 210 | 24.62 |
| 03:07 ET | 400 | 24.6 |
| 03:09 ET | 100 | 24.62 |
| 03:14 ET | 300 | 24.62 |
| 03:16 ET | 100 | 24.62 |
| 03:18 ET | 1399 | 24.64 |
| 03:20 ET | 100 | 24.65 |
| 03:21 ET | 400 | 24.65 |
| 03:23 ET | 2058 | 24.65 |
May 10, 2024
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), from 7:30PM ET on Friday May 10, 2024 by Dow Jones
7:30PM ET on Friday May 10, 2024 by Dow JonesDJ Mirum Pharmaceuticals Is Maintained at Overweight by Morgan Stanley, from 11:53AM ET on Friday May 10, 2024 by Dow Jones
11:53AM ET on Friday May 10, 2024 by Dow Jones
May 9, 2024
DJ Mirum Pharmaceuticals Is Maintained at Market Outperform by JMP Securities, from 2:49PM ET on Thursday May 09, 2024 by Dow Jones
2:49PM ET on Thursday May 09, 2024 by Dow JonesDJ Mirum Pharmaceuticals Is Maintained at Buy by Citigroup, from 1:55PM ET on Thursday May 09, 2024 by Dow Jones
1:55PM ET on Thursday May 09, 2024 by Dow JonesDJ Mirum Pharmaceuticals Price Target Maintained With a $40.00/Share by Cantor Fitzgerald, from 10:35AM ET on Thursday May 09, 2024 by Dow Jones
10:35AM ET on Thursday May 09, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Mirum Pharmaceuticals Inc | 1.2B | -6.5x | --- |
MannKind Corp | 1.2B | 198.3x | --- |
Xencor Inc | 1.3B | -10.1x | --- |
Aurinia Pharmaceuticals Inc | 759.4M | -13.2x | --- |
Arcturus Therapeutics Holdings Inc | 781.3M | -7.6x | --- |
Dynavax Technologies Corp | 1.4B | 224.7x | --- |
Company Information
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development and commercialization of therapies for debilitating rare and orphan diseases. It has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. It is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.
Contact Information
- Headquarters
- 950 Tower Ln Ste 1050FOSTER CITY, CA, United States 94404-4251
- Phone
- 650-667-4085
- Fax
- 302-269-3855
Executives
- Chairman of the Board
- Michael Grey
- President, Chief Operating Officer
- Peter Radovich
- Chief Executive Officer, Co-Founder, Director
- Christopher Peetz
- Principal Financial Officer
- Eric Bjerkholt
- Chief Development Officer
- Lara Longpre
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.2B |
|---|---|
Revenue (TTM) | $224.0M |
Shares Outstanding | 47.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.12 |
EPS | $-3.82 |
Book Value | $5.32 |
P/E Ratio | -6.5x |
Price/Sales (TTM) | 5.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -70.34% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
